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Monoacylglycerol lipase (MAGL) terminates the
signaling function of the endocannabinoid, 2-arachi-
donoylglycerol (2-AG). During 2-AG hydrolysis,
MAGL liberates arachidonic acid, feeding the prin-
cipal substrate for the neuroinflammatory prosta-
glandins. In cancer cells, MAGL redirects lipid stores
toward protumorigenic signaling lipids. Thus MAGL
inhibitors may have great therapeutic potential.
Although potent and increasingly selective MAGL
inhibitors have been described, their number is still
limited. Here, we have characterized piperazine and
piperidine triazole ureas that combine the high
potency attributable to the triazole leaving group
together with the bulky aromatic benzodioxolyl
moiety required for selectivity, culminating in com-
pound JJKK-048 that potently (IC50 < 0.4 nM)
inhibited human and rodent MAGL. JJKK-048 dis-
played low cross-reactivity with other endocanna-
binoid targets. Activity-based protein profiling of
mouse brain and human melanoma cell proteomes
suggested high specificity also among the metabolic
serine hydrolases.
INTRODUCTION
Monoacylglycerol lipase (MAGL) is a serine hydrolase, originally
characterized from the adipose tissue (Karlsson et al., 1997;
Labar et al., 2010), where it catalyzes the final step in lipolysis,
thereby liberating free fatty acids and glycerol for fuel or lipid
synthesis (Zechner et al., 2012). More recent findings have
brought MAGL to the center stage of endocannabinoid research
by uncovering the key role of this hydrolase in regulating the life-
time of the major endocannabinoid, 2-arachidonoylglycerol
(2-AG) (Blankman et al., 2007; Chanda et al., 2010; Schlosburg
et al., 2010). The endocannabinoids are involved in various phys-
iological and pathophysiological processes, including pain,
feeding, cognition, and emotions (Di Marzo et al., 2007; LongChemistry & Biology 20, 3et al., 2009b). In response to neural activity, 2-AG is synthesized
‘‘on demand’’ at postsynaptic sites, fromwhich it diffuses to acti-
vate presynaptic cannabinoid CB1 receptors (CB1Rs) in a retro-
grade manner, resulting in transient and long-lasting reduction
of neurotransmitter release (Di Marzo et al., 2007; Kano et al.,
2009). The signaling properties of 2-AG are strictly regulated
by the balanced action between biosynthetic and degradative
pathways. At the bulk brain level, MAGL accounts for 85% of
total 2-AG hydrolysis, and the remaining15% ismainly attribut-
able to two a/b-hydrolase domain (ABHD)-containing proteins,
namely ABHD6 and ABHD12 (Blankman et al., 2007; Savinainen
et al., 2012). The three 2-AG hydrolases are genuine monoa-
cylglycerol (MAG) lipases (i.e., they do not hydrolyze di- or
triacylglycerols) with not only distinct MAG substrate and isomer
preferences, but also unique inhibitor profiles (Navia-Paldanius
et al., 2012).
Recent studies have revealed unexpectedly that, in certain
tissues, like the brain, MAGL acts as the key metabolic switch
capable of linking together two lipid signaling systems: the
endocannabinoid and the eicosanoid systems (Mulvihill and
Nomura, 2012). This is because MAGL-catalyzed 2-AG hydro-
lysis generates arachidonic acid, and this fatty acid is the
precursor of cyclooxygenase-dependent production of eicosa-
noids, such as prostaglandins PGE2 and PGD2. In the brain,
MAGL-driven2-AGhydrolysiswasshown toprovide theprincipal
source of the neuroinflammatory prostaglandins; furthermore,
genetic or pharmacological MAGL inhibition has exerted anti-
inflammatory and neuroprotective effects in animal models of
Parkinson’s (Nomura et al., 2011) and Alzheimer’s disease
(Chen et al., 2012; Piro et al., 2012). In cancer cells, MAGL over-
expression has beenproposed to act as the keymetabolic switch
capable of redirecting lipids from storage sites toward the syn-
thesis of protumorigenic signaling lipids (Nomura et al., 2010;
Mulvihill and Nomura, 2012). Thus, MAGL can simultaneously
coordinatemultiple lipid signaling pathways in both physiological
and pathophysiological contexts. Collectively, these provocative
findings suggest that pharmacological inhibition of MAGL func-
tion may confer significant therapeutic benefits.
Although recent years have witnessed the development
of relatively potent and MAGL-selective inhibitors spanning
different chemical scaffolds, their numbers and selectivities are79–390, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 379
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et al., 2010; Feledziak et al., 2012; Fowler, 2012).Moreover, there
are some outstanding issues surrounding the potency of some
recently reported inhibitors, most notably JZL184 (Long et al.,
2009a; Savinainen et al., 2010; Holtfrerich et al., 2010). In addi-
tion, there are practically no activity data available regarding
compound SAR629, the covalent inhibitor cocrystallized with
MAGL (Bertrand et al., 2010). The present work was initiated to
provide answers to these questions. We consistently observed
lower than originally reported potency for JZL184 but did find
that SAR629 and its structural analogswere potent, albeit nonse-
lective, MAGL inhibitors. We systematically explored the impact
of the characteristics of the leaving group on MAGL inhibitor
potency and, based on these results, designed and synthesized
ultrapotent and highly selective MAGL inhibitors, culminating
in the preparation of two piperidine triazole ureas, JJKK-046
and JJKK-048. The inhibitors were thoroughly characterized in
various functional assays using rodent and human enzyme prep-
arations; these studies indicated that compound JJKK-048 is the
most potent and MAGL-selective inhibitor designed so far.
RESULTS
The O-aryl carbamate JZL184 was initially reported to be
a potent and specific MAGL inhibitor, with IC50 value of 2 nM
for the mouse and human enzymes and 25 nM for the rat enzyme
under in vitro conditions (Long et al., 2009a). It has also been re-
ported that JZL184 is 10- to 100-fold less potent against rat
than mouse and human MAGL (Long et al., 2009b). Using
various assay formats, we (Savinainen et al., 2010) and others
(Holtfrerich et al., 2010) were unable to confirm such high
potency for this compound toward human MAGL. To further
explore this discrepancy, we extended the MAGL assay reper-
toire by devising and validating a sensitive fluorometric glycerol
assay (Navia-Paldanius et al., 2012). This assay allowed moni-
toring of the glycerol output from 2-AG hydrolysis catalyzed by
both MAGL and the related 2-AG hydrolases ABHD6 and
ABHD12 that together account for 99% of 2-AG hydrolysis in
brain membrane preparations (Blankman et al., 2007; Savi-
nainen et al., 2012). Using this assay, we evaluated the inhibitor
behavior of methylarachidinoyl fluorophosphonate (MAFP),
N-arachidonoylmaleimide (NAM), and JZL184 in rat and mouse
brain membrane preparations. As expected (Saario et al., 2004),
the broadly acting serine hydrolase inhibitor, MAFP, potently
(IC50  1 nM) and comprehensively prevented 2-AG hydrolysis
in these preparations (Figure 1A). In line with previous findings
(Saario et al., 2005), the MAGL-preferring inhibitor NAM blocked
80% of brain 2-AG hydrolysis with the expected potency
(IC50  150–300 nM), leaving 20% residual activity in both
preparations. Similarly, the MAGL-selective inhibitor JZL184
prevented 80% of brain 2-AG hydrolysis with 20% residual
activity. The NAM- and JZL184-resistant component has been
principally attributed to ABHD6 and ABHD12 (Blankman et al.,
2007; Savinainen et al., 2012). As in our previous studies with
human MAGL (Savinainen et al., 2010), JZL184 was effective in
the micromolar-high nanomolar range (IC50 values rat 3 mM,
mouse 0.1 mM) (Figure 1A). Thus, in line with previous findings,
we observed a 30-fold potency difference in the ability of
JZL184 to inhibit mouse and human (Savinainen et al., 2010)380 Chemistry & Biology 20, 379–390, March 21, 2013 ª2013 Elsevieversus rat MAGL species, albeit with IC50 values in the micro-
molar-high nanomolar range.
Functional autoradiography represents a convenient tech-
nique to monitor endocannabinoid-dependent, CB1R-mediated
Gi/o protein activity in inhibitor-treated brain sections. We have
previously shown that, in rat brain sections, MAFP can activate
this cascade indirectly (no direct activity at CB1R) as a conse-
quence of 2-AG accumulation and subsequent 2-AG-driven
CB1R activation (Paloma¨ki et al., 2007). We used this approach
to determine whether two MAGL inhibitors, NAM and JZL184,
could mimic MAFP in this setup. As shown in Figure 1B, the
two inhibitors were ineffective, suggesting either that their
potency was not sufficient (i.e., in confirmation of the hydrolase
assays) or that, in addition to MAGL, MAFP targets the other
2-AG hydrolases, ABHD6 and/or ABHD12 in particular, and the
inhibition of these hydrolases accounts for the MAFP-evoked
signal. Thus we treated brain sections with the broad spectrum
lipase inhibitor tetrahydrolipstatin (THL) (orlistat) that is known
to potently target both ABHD6 and ABHD12 (Navia-Paldanius
et al., 2012), as well as with WWL70, an ABHD6-selective inhib-
itor (Li et al., 2007; Navia-Paldanius et al., 2012). As is evident
from Figure 1B, these inhibitors failed to evoke the MAFP-
mimicking response. Since MAGL accounts for the bulk of
2-AG hydrolysis in brain tissue, we decided to seek more effec-
tive MAGL inhibitors.
SAR629 and the AKU Series of Compounds
The crystal structure of humanMAGL was resolved in a complex
with the covalent piperazine triazole urea inhibitor, SAR629
(Bertrand et al., 2010). The same report also stated that
SAR629 works in the nanomolar activity range, although no
data were presented to substantiate that claim. We therefore
synthesized SAR629 (JJKK-033 in our compound series) and
a series of piperazine triazole urea compounds (the AKU series)
inspired by the SAR629 chemical structure and evaluated the
potency of these compounds toward MAGL in rodent brain
membrane preparations. These studies indicated that SAR629
and its close structural analog AKU-005 inhibited MAGL activity
at subnanomolar potencies (IC50 values 0.2–1.1 nM) (Table 1).
Triazole versus p-Nitrophenoxy as the Leaving Group
To explore the importance of the triazole moiety for MAGL inhib-
itor potency, we replaced the triazole-leaving group of SAR629
with that of JZL184 (p-nitrophenoxy) with the outcome that the
compound thus generated (AKU-015) showed >1,000-fold drop
in potency in rodent brain membranes as compared to SAR629
(Table 1). Similarly, replacing the triazole moiety of AKU-005
with p-nitrophenoxy (compound AKU-003) resulted in >1,000-
fold loss of inhibitor potency. Another p-nitrophenoxy-containing
compound, termed JZL195, has been described as a potent,
dual fatty acid amide hydrolase (FAAH)-MAGL inhibitor (IC50
values of 4 nM for human recombinant and mouse brain MAGL
preparations) (Long et al., 2009b). We synthesized this
compound (JJKK-004 in our compound series) and found that
it inhibited MAGL activity with micromolar potency (IC50 values
of 3.7 mM and 3.3 mM for rat and mouse MAGL, respectively)
(Table 1). However, the replacement of the p-nitrophenoxy group
of JZL195 with the triazole moiety resulted in a dramatic
(>25,000-fold) increase in inhibitor potency, as observed for ther Ltd All rights reserved
Figure 1. Comparative In Vitro Evaluation of the 2-AG Hydrolase Inhibitors MAFP, JZL184, and NAM
(A) Dose-response curves for MAFP, NAM, and JZL184 to inhibit 2-AG hydrolysis in rat cerebellar (Rcm) and mouse whole brain (Mbm) membranes. Membranes
were pretreated for 30 min with DMSO (control) or with the indicated concentrations of the inhibitors. Glycerol liberated from 2-AG hydrolysis was determined as
described in Experimental Procedures. The data points aswell as the logIC50 values shown in the box aremeans ± SEM from three independent experiments. IC50
values (mean) are shown in parenthesis. Note that, in contrast to MAFP, which comprehensively blocks 2-AG hydrolysis, 20% residual activity remains after
maximally effective concentrations of the MAGL-selective inhibitors NAM and JZL184 (dashed horizontal line).
(B) Functional autoradiography visualizing endocannabinoid-dependent, CB1R-mediated Gi/o protein activity. Basal represents G protein activity in the absence
of added agonist. Pretreatment with MAFP results in endogenous 2-AG accumulation and subsequent CB1R activity in brain regions, such as the caudate
putamen (CPu), the cerebral cortex (Cx), the hippocampus (Hip), and the molecular layer of the cerebellum (Cbm). For comparative purposes, CB1R response to
the synthetic cannabinoid agonist CP55,940 is shown. Note that, in contrast to MAFP, theMAGL-selective inhibitors NAM and JZL184 do not generate the CB1R
signal. Similarly, the broad spectrum lipase inhibitor THL (orlistat) or the ABHD6-selective inhibitor WWL70 do not evoke the MAFP-mimicking response. Scale
bar, 2mm. The data are representative images from at least three independent experiments. Three images in (B) (Basal, MAFP 106 M and CP55,940 53 106 M)
were previously presented in a review article illustrating CB1R activity evoked by endogenous and exogenous cannabinoid agonists (Savinainen et al., 2012).
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demonstrate that the nanomolar potency of the piperazine deriv-
atives SAR629, AKU-005, and JJKK-006 toward MAGL is deter-
mined by the triazole moiety and that the p-nitrophenoxy acts as
a poor leaving group.
Triazole and Bulky Benzhydryl Group on the
4-Piperazine Position Are Essential for the High MAGL
Inhibitor Potency
Since the triazole moiety was shown be a superior leaving group,
we examined subsequently whether benzotriazole, triazolopyri-Chemistry & Biology 20, 3dine, or imidazole leaving groups were as effective. The compar-
ative evaluation (Table 2) indicated that the benzotriazole (AKU-
006) and triazolopyridine (AKU-002 and AKU-009) derivatives
were somewhat less potent (7-fold and 2-fold, respectively)
than the corresponding triazole analogs and that inhibitor
potency was dramatically (>8,000-fold) reduced with the imid-
azole leaving group, as evidenced for the compound AKU-004.
In order to substantiate the importance of the bulky benzhydryl
substituent on the 4-piperazine position for MAGL inhibition,
we synthesized phenyl (AKU-009 and AKU-010) and ethoxy-
carbonyl-substituted piperazines (AKU-033 and AKU-034). As79–390, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 381
Table 1. MAGL Inhibitor Potency in Rat and Mouse Brain Membranes for Compounds with Either a Triazole or a p-Nitrophenoxy
Leaving Group
Inhibitor R1 R2 Rat (Rcm) logIC50, Mean ± SEM (IC50) Mouse (Mbm) logIC50, Mean ± SEM (IC50)
JJKK-033 (SAR629) 8.94 ± 0.08 (1.1 nM) 9.66 ± 0.06 (219 pM)
AKU-015 5.75 ± 0.10 (1.8 mM) 6.55 ± 0.05 (282 nM)
AKU-005 9.23 ± 0.11 (589 pM) 9.51 ± 0.07 (309 pM)
AKU-003 5.81 ± 0.07 (1.5 mM) 6.50 ± 0.05 (316 nM)
JJKK-006 10.12 ± 0.06 (76 pM) 9.90 ± 0.08 (126 pM)
JJKK-004 (JZL195) 5.43 ± 0.06 (3.7 mM) 5.48 ± 0.06 (3.3 mM)
Data are mean ± SEM from three independent experiments. See also Figure S1 and Table S2.
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steric hindrance declined with the phenyl (60- to 74-fold for rat
MAGL and 220-fold for mouse MAGL) or polar ethoxycarbonyl
groups (250-fold for rat MAGL and 1,000-fold for mouse
MAGL) (Table 2). Collectively, these results indicate that, in addi-
tion to the triazole moiety, triazolopyridine and benzotriazole
(but not imidazole) can serve as good leaving groups without
severely compromising inhibitor potency. Furthermore, sub-
stituting the bulky benzhydryl moiety with phenyl or ethoxycar-
bonyl dramatically reduced MAGL inhibitor potency. Interest-
ingly, this effect was more dramatic in the case of mouse MAGL.
Selected compounds from the AKU series were tested in func-
tional autoradiography, where it was observed that AKU-005,
AKU-009, and AKU-010 all evoked MAFP-mimicking and
AM251-sensitive [35S]GTPgS binding responses (Figure S1
available online). In addition, the MAFP-mimicking response
was reproduced by AKU-002 and AKU-006 throughout the
CB1R-responsive brain regions, but surprisingly, this response
was not reversed by the CB1R-selective antagonist AM251 (Fig-
ure S1). We have currently no additional data to explain the
differential behavior of the latter two compounds in this assay.
FAAH Is an Off Target of the Triazole and Piperazine
Derivatives
Although the triazole and piperazine derivatives SAR629, AKU-
005, and JJKK-006 showed excellent potency toward MAGL,
we were concerned about the potential off targets of these inhib-
itors, FAAH in particular. Indeed, FAAH activity assays indicated382 Chemistry & Biology 20, 379–390, March 21, 2013 ª2013 Elseviethat AKU-005 inhibited rat and human FAAH with IC50 values
(mean ± SEM, n = 3) of 63 ± 8 nM and 389 ± 65 nM, respectively.
For the rat enzymes, this indicated that AKU-005 possessed
relatively poor (100-fold) MAGL selectivity over FAAH. In sup-
port, molecular docking studies based on the rat FAAH crystal
structure indicated that all three inhibitors fit similarly into the
FAAH active site (Figure S2).
Combining Bulky Aromatic Substituents Together
with the Triazole Leaving Group Yields Ultrapotent
MAGL-Selective Inhibitors
Although we could not confirm the high potency originally
attributed to JZL184, this compound is known to exhibit good
selectivity for MAGL over other metabolic serine hydrolases,
as revealed using competitive activity-based protein profiling
(ABPP) with mouse brain membrane proteome (Long et al.,
2009a, 2009b). The high MAGL selectivity has been attributed
to the bulky aromatic benzodioxolyl groups, and this informa-
tion has been successfully utilized in the recent design of the
second generation MAGL-selective inhibitor O-hexafluoroiso-
propyl (HFIP) carbamate KML29 (Chang et al., 2012). Thus, in
order to generate highly potent and MAGL-selective inhibitors,
we decided to explore combining the high potency afforded
by the triazole moiety with the bulkiness provided by the
aromatic methylene-3,4-dioxyphenyl substituents and further
enhancing selectivity toward MAGL by changing the piperazinyl
moiety to piperidinyl ring of JZL184. Our original plan was to
replace the p-nitrophenoxy leaving group of JZL184 with ther Ltd All rights reserved
Table 2. MAGL Inhibitor Potency for Compounds with Triazole, Triazolopyridine, Benzotriatzole, and Imidazole Leaving Group or with
4-Piperazine Substitution
Inhibitor Rat (Rcm) logIC50, Mean ± SEM (IC50) Mouse (Mbm) logIC50, Mean ± SEM (IC50)
AKU-002
8.85 ± 0.04 (1.4 nM) 9.12 ± 0.07 (759 pM)
AKU-005
9.23 ± 0.11 (589 pM) 9.51 ± 0.07 (309 pM)
AKU-006 (ML30)
8.36 ± 0.03 (4.4 nM) 8.72 ± 0.07 (1.9 nM)
AKU-004
5.32 ± 0.09 (4.8 mM) 5.59 ± 0.07 (2.6 mM)
AKU-009
6.98 ± 0.06 (105 nM) 6.80 ± 0.11 (158 nM)
AKU-010
7.45 ± 0.09 (35 nM) 7.17 ± 0.08 (68 nM)
AKU-033
6.48 ± 0.07 (331 nM) 6.16 ± 0.04 (692 nM)
AKU-034
6.81 ± 0.09 (155 nM) 6.42 ± 0.06 (380 nM)
Data are mean ± SEM from three independent experiments. See also Figure S1 and Table S2.
Chemistry & Biology
Ultrapotent Inhibitors of Monoacylglycerol Lipasetriazole. However, during the synthetic process, we noted
that the intermediate needed for the synthesis of JZL184,
bis(benzo[d][1,3]dioxol-5-yl)(piperidin-4-yl)methanol, was very
labile, eliminating the hydroxyl group during storage. Therefore,Chemistry & Biology 20, 3instead we synthesized analogs of the stable elimination in-
termediates (the methylene-piperidine and its hydrogenation
product) to obtain the piperidine triazole ureas JJKK-046 and
JJKK-048. In fact, these compounds proved to be the most79–390, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 383
Table 3. MAGL Inhibitor Potency of JJKK-046 and JJKK-048 in Comparison with the Recently Described MAGL Inhibitors ML30 and
KML29
Inhibitor
Rat (Rcm) logIC50,
Mean ± SEM (IC50)
Mouse (Mbm) logIC50,
Mean ± SEM (IC50)
hMAGL logIC50,
Mean ± SEM (IC50)
JJKK-046
9.57 ± 0.07 (269 pM) 9.72 ± 0.04 (191 pM) 9.25 ± 0.05 (562 pM)
JJKK-048
9.67 ± 0.09 (214 pM) 9.56 ± 0.03 (275 pM) 9.44 ± 0.05 (363 pM)
AKU-006 (ML30)
8.36 ± 0.03 (4.4 nM) 8.72 ± 0.07 (1.9 nM) 8.83 ± 0.36 (1.5 nM)
KML29
8.60 ± 0.05 (2.5 nM) 9.07 ± 0.08 (851 pM) 8.44 ± 0.05 (3.6 nM)
IDFP
9.97 ± 0.05 (107 pM) 9.66 ± 0.06 (219 pM) 8.81 ± 0.03 (1.5 nM)
For comparative purposes, the potency of IDFP is also shown. Data are mean ± SEM from three independent experiments. See also Figures S3–S5.
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compounds inhibited human, rat, andmouseMAGLpreparations
with the IC50 values in the subnanomolar range (Table 3). Interest-
ingly, the chemical structure of AKU-006 in our compound series
is identical to that ofML30, a recently described benzotriazol-1-yl
carboxamide-based,MAGL inhibitorwith a reported IC50 value of
0.54 nM for purified human MAGL (Morera et al., 2012). In our
assays, the IC50 values for ML30 (AKU-006) were 4.4, 1.9, and
1.5 nM for rat, mouse, and human MAGL preparations, respec-
tively (Table 3). Thus, when tested under identical conditions,
the potency of JJKK-046 was 3- to 10-fold higher in the three
MAGL preparations and that of JJKK-048 4- to 20-fold higher384 Chemistry & Biology 20, 379–390, March 21, 2013 ª2013 Elseviewhencompared toML30.KML29,which contains the samebulky
aromatic benzodioxolyl groups as JJKK-046 and JJKK-048, has
been reported to display IC50 values of 43, 15, and 5.9 nM toward
rat, mouse, and human MAGL (Chang et al., 2012). As KML29
was commercially available, we evaluated this compound in our
assay and obtained slightly higher potency values than those in
the original study. In our assay, the IC50 values for KML29 were
2.5, 0.9, and 3.6 nMwith the rat, mouse, and humanMAGL prep-
arations (Table 3). It is notable that thepotencies of JJKK-046and
JJKK-048 exceeded those of KML29 by 3- to 10-fold, depending
on the MAGL preparation. For the rat and human MAGL, JJKK-
046 and JJKK-048 were 10-fold more potent than KML29,r Ltd All rights reserved
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The nonselective serine hydrolase inhibitor isopropyl dodecyl-
fluorophosphonate (IDFP) is probably the most potent MAGL
inhibitor identified to date, with an IC50 value of 0.8 nM for human
MAGL (Nomura et al., 2008). For comparative purposes, we eval-
uated IDFP against the three MAGL preparations and found the
IC50 values of 0.1, 0.2, and 1.5 nM for the rat, mouse, and human
MAGL (Table 3). Overall, the potencies of JJKK-046 and JJKK-
048 compare favorably with those of the previously reported
high-potency inhibitors.
Proposed Mechanism of MAGL Inhibition by JJKK-048
In competitive ABPP, JJKK-048 prevented TAMRA-fluoro-
phosphonate (FP) labeling of the MAGL active site serine
(S122), suggesting that the inhibitor probably targets this cata-
lytic residue (Figure S3A). Fast dilution of JJKK-048-treated
MAGL preparation did not result in time-dependent drop of
inhibitor potency, suggesting further that JJKK-048 (similarly to
the established irreversibly acting inhibitor MAFP) inhibited
MAGL in a covalent manner (Figure S3B). We therefore propose
that the triazole (1,2,4-triazolate anion) acts as the leaving group
and that JJKK-048 binds to the active site S122, forming a carba-
mate adduct (Figure S3C). A similar reaction mechanism has
been proposed for the triazole compound SAR629 (Bertrand
et al., 2010). Despite extensive efforts, we could not unambigu-
ously confirm the presence of the JJKK-048-MAGL adduct with
a mass spectrometric approach (see Supplemental Results).
In functional autoradiography, JJKK-046 and JJKK-048
evoked the MAFP-mimicking and AM251-sensitive [35S]GTPgS-
binding responses (Figure 2A). This was not due to direct
CB1R activation, as in membrane [35S]GTPgS-binding assays
assessing direct CB1R agonism, these compounds showed
no agonist activity at CB1R (or CB2R) at concentrations up to
105 M (Table S1). Thus, the MAFP-mimicking CB1R activity
wasdue to inhibition of 2-AG (but not arachidonoyl ethanolamide,
anandamide [AEA]) hydrolysis (see below). Notably, JJKK-
046 showed moderate CB1R antagonist activity at concen-
trations R106 M (Table S2), a finding likely explaining the
relatively modest response for this compound in functional
autoradiography.
JJKK-048 Exhibits Remarkable MAGL Selectivity
Liquid chromatography-tandem mass spectrometry (LC-MS/
MS) analysis of endocannabinoid levels in inhibitor-treated brain
sections indicated that JJKK-046 and JJKK-048, when tested at
1 mM final concentration (i.e., 3,700- and 4,700-fold higher
concentrations than their respective IC50 values for MAGL),
selectively increased tissue levels of 2-AG but not those of
AEA (Figure 2B). However, tissue AEA levels were significantly
elevated with 105 M JJKK-046. In the same experiment,
SAR629 and AKU-005 elevated tissue levels of both 2-AG and
AEA, as would be expected from their potent dual inhibitory
action on MAGL and FAAH.
Activity assays using rat and human FAAH preparations re-
vealed that the two inhibitors exhibited notable MAGL selectivity
over FAAH (JJKK-046 > 1,200-fold, JJKK-048 > 13,000-fold)
(Table 4). Activity assays with human ABHD6 indicated that
JJKK-046 possessed moderate inhibitor activity toward human
ABHD6 (hABHD6) (160-fold MAGL selectivity), whereas forChemistry & Biology 20, 3JJKK-048, the MAGL/ABHD6 selectivity ratio was 630-fold
(Table 4). When tested at concentrations up to 106 M, human
ABHD12 was resistant to these inhibitors (Table 4). Collectively,
these data indicate that JJKK-048 in particular shows re-
markable selectivity for MAGL over the other endocannabinoid
hydrolases.
Competitive ABPP of serine hydrolases in mouse brain
membrane proteome using TAMRA-FP indicated that MAGL
was the only detectable target of JJKK-046 or JJKK-048 at
concentrations up to 107 M (Figure S4). However, at higher
concentrations (106 and 105 M), JJKK-046, and JJKK-048 to
a lesser extent, inhibited TAMRA-FP labeling of ABHD6 and
FAAH as well as labeling of unidentified serine hydrolases
migrating at 22–23 kDa and 28–30 kDa. With these ex-
ceptions, no additional targets were evident (Figure S4). As
JJKK-048 exhibited higher MAGL selectivity than JJKK-046 in
all functional assays, we chose this inhibitor for further studies
with intact cells.
JJKK-048 Potently Inhibits MAGL Activity in Living Cells
We evaluated the inhibitory activity of JJKK-048 in intact
HEK293 cells transiently overexpressing human MAGL (hMAGL)
(Navia-Paldanius et al., 2012) and observed that 1 hr treatment
with JJKK-048 inhibited 2-AG hydrolysis in a dose-dependent
manner (Figure 3A). Significant inhibition was achieved already
at 109 M concentration, and MAGL blockade was maximal
at 108 M concentration. As recent studies have implicated
MAGL in promoting tumor cell malignancy (Nomura et al.,
2010), we screened a panel of human melanoma cells using
ABPP with TAMRA-FP to reveal the cell lines with high endoge-
nous MAGL expression (Figure 3B). From the tested cells lines
(MV3, C8161, A2058, and WM115), C8161 showed the highest
MAGL expression; this was evident in both lysate andmembrane
proteomes. In competitive ABPP, JJKK-048 (107 M) selectively
blocked TAMRA-FP labeling of both the33 and35 kDa forms
of MAGL. Importantly, ABPP revealed no additional targets
among the serine hydrolases in any of the cell lines, further
demonstrating high MAGL selectivity of JJKK-048 also in pro-
teomes of human melanoma cells. Treatment of C8161 cells
for 1 hr with the MAGL inhibitors JJKK-048 (108 or 107 M) or
JZL184 (106 M) inhibited 2-AG hydrolase activity to the same
extent (Figure 3C). Collectively, these experiments demonstrate
that JJKK-048 potently inhibits MAGL activity also in intact
human cells. Thus, we explored further whether pharmacological
MAGL inhibition would have any impact on C8161 cell prolifera-
tion, migration, and invasiveness. As a reference inhibitor, we
used JZL184 (106 M) in these experiments. However, in con-
trast to expectations, we found that neither JJKK-048 nor
JZL184 could alter these parameters in any statistically signifi-
cant manner in the studied C8161 melanoma cell line (Figure S6;
Supplemental Discussion).
DISCUSSION
The present paper describes the design and characterization of
ultrapotent MAGL inhibitors with remarkable selectivity over
other serine hydrolases as well as other targets of the endocan-
nabinoid system. In a nutshell, the in vitro potencies of the
compounds JJKK-046 and JJKK-048 exceed those of current79–390, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 385
Figure 2. The MAGL Inhibitors JJKK-046 and JJKK-048 Activate CB1Rs Indirectly through Elevating Brain 2-AG Levels
(A) The inhibitors evoke MAFP-mimicking and AM251-sensitive, [35S]GTPgS-binding responses in functional autoradiography. CB1R-dependent G protein
activity is evident in various brain regions, including the CPu, the Cx, the Hip, and the molecular layer of the Cbm. For comparative purposes, response to the
synthetic cannabinoid agonist CP55,940 is also shown. Scale bar, 2 mm. The experiment was repeated twice with similar outcome.
(B) JJKK-048 selectively increases 2-AG levels in rat brain sections. Sections were treated for 1 hr with the indicated concentrations of the inhibitors, washed, and
incubated thereafter for 90 min in assay buffer. The buffer was removed and tissue endocannabinoid content determined with LC-MS/MS, as detailed in
Experimental Procedures. For reference purposes, the global serine hydrolase inhibitor, MAFP, and the FAAH-selective inhibitor, PF-750, were included. Values
are mean + SEM from triplicate slides with two horizontal brain sections in each. Statistical comparison was performed using one-way Anova followed by Tukey’s
multiple comparisons. Significance level ***p < 0.001.
See also Figures S2 and S4, and Table S1.
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Ultrapotent Inhibitors of Monoacylglycerol Lipasetop of the line inhibitors JZL184, ML30, and KML29 in rat and
mouse MAGL preparations when evaluated under identical
conditions (Table 3). While JZL184 has been in use for some
time, ML30 and KML29 were disclosed only recently, while our
study was in progress. From a chemical perspective, KML29
(Chang et al., 2012) is a variant of JZL184, with the p-nitrophe-
noxy leaving group replaced with an HFIP group, and ML30 is
a piperazine-based benzotriazole urea (Morera et al., 2012),386 Chemistry & Biology 20, 379–390, March 21, 2013 ª2013 Elseviea compound independently synthesized for the present study
(AKU-006 in our compound series). These compounds as well
as the broadly acting serine hydrolase inhibitor IDFP, which is
perhaps the most potent MAGL inhibitor identified to date,
were evaluated in our assays to facilitate direct comparison
under identical assay conditions, and both ML30 and KML29
were shown to be less potent than JJKK-046 and JJKK-048
that we report here.r Ltd All rights reserved
Table 4. Inhibitor Activity of JJKK-046 and JJKK-048 Toward
Other Mammalian Endocannabinoid Hydrolases with the MAGL
Selectivity Ratio Indicated
Endocannabinoid Hydrolase
JJKK-046 JJKK-048
log[IC50] ± SEM log[IC50] ± SEM
(IC50) (IC50)
rat FAAH 6.52 ± 0.04
(302 nM)
5.62 ± 0.05
(2.4 mM)
rMAGL/rFAAH selectivity 1,226 11,226
hFAAH 6.00 ± 0.07
(1 mM)
5.32 ± 0.05
(4.8 mM)
hMAGL/hFAAH selectivity 1,778 13,183
hABHD6 7.05 ± 0.03
(89 nM)
6.64 ± 0.02
(229 nM)
hMAGL/hABHD6 selectivity 158 631
hABHD12 remaining activity,
98.1% ± 0.3% at
106 M
remaining activity,
91.7% ± 0.3% at
106 M
Data are mean ± SEM from three independent experiments. See also
Figures S4 and S7.
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of MAGL Inhibitor Potency
We demonstrated the importance of the leaving group char-
acter (triazole versus p-nitrophenoxy) for MAGL inhibitor
potency, as >1,000-fold reduction in potency was observed
for compounds with otherwise identical structures after switch-
ing the triazole moiety to p-nitrophenoxy group. Leaving groups
whose conjugate acids have low pKa values are generally more
reactive than those with high pKa’s. To examine this in further
detail, we collected the experimental and calculated pKa values
of the conjugate acids of the leaving groups present in our
inhibitors (Table S2). The pKa values in combination with the
observed inhibitor potency allowed us to conclude that inhibi-
tors having their leaving group’s conjugate acid pKa between
8 and 11 are optimal for MAGL inhibition, as demonstrated for
inhibitors with triazole (pKa 10.0), benzotriazole (pKa 8.2), or
hexafluoroisopropyl alcohol (pKa 9.3) leaving groups. The low
MAGL potency of p-nitrophenoxy-based inhibitors may be ex-
plained by the low pKa of the p-nitrophenol (7.15), suggesting
that the inhibitor is too labile (reactive) under the assay con-
ditions employed, releasing p-nitrophenoxy group before
reaching the active site of MAGL. Imidazole, however, seems
to be a too weak acid (pKa 14.4) and therefore it acts as
a poor leaving group, as evidenced by the low potency of the
imidazole-based inhibitor AKU-004. The high potency of IDFP
(a fluorophosphonate with C12:0 acyl chain) toward MAGL is
consistent with the MAG substrate preferences of this enzyme,
showing the highest activity toward medium to long chain-
saturated (C8:0–C12:0) MAGs (Navia-Paldanius et al., 2012).
In various MAGL preparations, IDFP was 10-fold more potent
than MAFP (present findings, Savinainen et al., 2010), indicating
that, in addition to the pKa value of the leaving group, the length
and degree of saturation of the acyl chain has a notable
effect on the inhibitor potency of the fluorophosphonate MAG
analogs.Chemistry & Biology 20, 3Selectivity over FAAH
We found that SAR629 and its structural analogs were potent
dual MAGL-FAAH inhibitors with limited MAGL selectivity.
ML30 has been reported to be a potent (IC50 0.54 nM) hMAGL
inhibitor with a 1,000-fold selectivity versus FAAH (Morera
et al., 2012). In agreement, we witnessed a closely matching
potency (IC50 1.5 nM) for ML30 toward hMAGL. We did not eval-
uate ML30 for FAAH inhibitor activity, but its closest structural
analog (AKU-005) showed 100-fold MAGL selectivity over
FAAH. We improved selectivity of our compound series by
combining the potency conferred by the triazole moiety together
with the selectivity offered by the bulky aromatic benzodioxolyl
groups, originally incorporated in the JZL184 chemical structure
(Long et al., 2009a). Although JJKK-046 showed >1,000-fold
MAGL selectivity over FAAH, the selectivity could be further
increased by almost 10-fold in the case of JJKK-048, with the
only structural difference between these compounds being
the double (JJKK-046) versus single (JJKK-048) bond linking
the piperidine and benzodioxolyl moieties. Molecular modeling
indicated that both compounds yielded similar sets of well-
converged docking poses in the case of MAGL (Figure S7),
consistent with the similar potencies of both compounds toward
MAGL. In the case of FAAH, JJKK-048 was able to bind in the
reactive orientation only when a flexible induced fit docking
was used (Figure S7), a finding that could potentially explain
the enhanced MAGL selectivity of JJKK-048. Thus, from
the currently available MAGL inhibitors, both JJKK-048 and
KML29 (Chang et al., 2012) show excellent (>10,000-fold)
MAGL selectivity over FAAH.
Selectivity over ABHD6 and Other Serine Hydrolases
ABHD6 was the closest off target of our inhibitors JJKK-046 and
JJKK-048 with160- and630-fold hMAGL selectivity, respec-
tively, over hABHD6. Similarly, ABHD6 was the closest off target
of the structurally related compound KML29 in the mouse brain
membrane proteomewith a reported >100-foldMAGL selectivity
(Chang et al., 2012). These findings suggest that the active
sites of MAGL and ABHD6 probably share common structural
elements. MAGL crystal structures are available, and these
have revealed a lid domain guarding the entrance of a relatively
large, occluded hydrophobic tunnel with the active site buried at
its bottom (Bertrand et al., 2010; Labar et al., 2010; Schalk-Hihi
et al., 2011; Figure S5). No crystal structure for ABHD6 is
currently available to allow stringent comparison. However,
hMAGL and hABHD6 share also similar MAG substrate prefer-
ences (Navia-Paldanius et al., 2012), suggesting further that
both ligand access and the active site dimensions of these
hydrolases must be closely related. Collectively, this information
may explain why ABHD6 is the closest off target of even the
highly MAGL-selective inhibitors, such as JJKK-048 and KML29.
Interestingly, ABHD12 was not sensitive to JJKK-048 at con-
centrations up to 106 M, suggesting that the entrance and/or
active site of this 2-AG hydrolase is quite distinct from those of
MAGL and ABHD6. This is supported also by the more restricted
substrate and inhibitor profiles of human ABHD12 as compared
to hMAGL and hABHD6 (Navia-Paldanius et al., 2012; present
study). ABPP of mouse brain and human proteomes demon-
strated further high MAGL selectivity of JJKK-048 over other
metabolic serine hydrolases.79–390, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 387
Figure 3. JJKK-048 Potently Inhibits MAGL in Intact Human Cells
(A) Treatment for 1 hr with JJKK-048 inhibits MAGL activity in intact HEK293 cells overexpressing hMAGL. For comparative purposes, the response to JZL184
(106 M) is shown.
(B) ABPP of serine hydrolases in membranes and lysates of human melanoma cell lines using the TAMRA-FP probe reveals highest MAGL expression in C8161
cells, evident both in membranes and lysates (squares). Treatment for 1 hr with JJKK-048 (107 M) selectively blocks TAMRA-FP labeling of both the 33 and
35 kDa forms of MAGL, with no additional targets evident in any of the cell lines. To facilitate localization of MAGL, mouse whole brain membranes (MBM) were
run in the same gel.
(C) Treatment of intact C8161melanoma cells for 1 hr with JJKK-048 or JZL184 at the indicated doses significantly inhibited 2-AG hydrolase activity, as assessed
from lysates of inhibitor-treated cells. Values are means ± SD of duplicate determinations from one experiment that was repeated twice with similar outcome.
See also Figure S6 and Supplemental Discussion.
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In the light of recent findings highlighting beneficial effects of
MAGL inhibition in neurodegeneration and cancer progress,
the advantages and potential pitfalls of pharmacological MAGL
inhibition need to be carefully considered. For example, chronic
MAGL inactivation may not be a desirable goal, as previous find-
ings in mice with pharmacological or genetic MAGL blockade
indicate that this leads to 2-AG overflow and functional antago-
nism of the endocannabinoid system (Chanda et al., 2010;
Schlosburg et al., 2010). However, the partial blockade achieved
by a low dose of covalent inhibitor, such as JZL184 (Busquets-
Garcia et al., 2011), or by an intermittent dosage regimen could
still be able to produce the desired therapeutic effects that could
be maintained under chronic treatments. The latter approach
has provided promising results in being able to diminish amyloid
neuropathology in Alzheimer’s disease animal models without
compromising cannabinoid receptor integrity (Chen et al.,388 Chemistry & Biology 20, 379–390, March 21, 2013 ª2013 Elsevie2012). An as yet unexplored issue is the utility of reversibly acting
MAGL inhibitors, either synthetic (Schalk-Hihi et al., 2011) or
natural, the latter being exemplified by the triterpene and pristi-
merin (King et al., 2009). It could be anticipated that, in contrast
to the covalently acting MAGL inhibitors, the reversible inhibitors
might produce only a partial inhibition that should leave the
endocannabinoid system intact. Whether such a partial MAGL
blockade is sufficient to mediate any therapeutic effects remains
to be seen. This should be one avenueworth exploring further, as
the triterpene family of natural products is known to possess
both anticancer and anti-inflammatory properties (Petronelli
et al., 2009), some of which may be attributable to inhibition of
2-AG hydrolases, including MAGL. Finally, selective inhibition
of additional brain 2-AG hydrolases, such as ABHD6, may also
elicit anti-inflammatory and neuroprotective effects, as recently
observed in amousemodel of traumatic brain injury (Tchantchou
and Zhang, 2012).r Ltd All rights reserved
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The recent surprising findings showing that MAGL-
catalyzed hydrolysis of the endocannabinoid 2-AG provides
the principal substrate for the production of neuroinflamma-
tory prostaglandins, together with findings implicating
MAGL as a metabolic switch promoting protumorigenic
signaling lipids, imply that pharmacological inhibition of
MAGL activity may have therapeutic benefits in the treat-
ments of neurodegenerative disease and cancer. In addition,
MAGL inhibition may hold promise in the treatment of meta-
bolic disorders, such as diet-induced insulin resistance
(Taschler et al., 2011). We have designed and characterized
in detail some piperazine and piperidine triazole ureas as
MAGL inhibitors. This work culminated in the synthesis of
compound JJKK-048, which is the most potent and MAGL-
selective inhibitor currently available. Together with recent
reports from other laboratories describing compounds
ML30 (Morera et al., 2012) and KML29 (Chang et al., 2012),
these findings indicate that a pharmacological toolkit con-
sisting of potent and increasingly MAGL-selective inhibitors
with varying chemical scaffolds is now available. This toolkit
can be used in further studies to explore the consequences
of pharmacological MAGL inhibition in experimental models
of cancer, neurodegeneration, and metabolic disease. From
the medicinal chemistry point of view, the MAGL-selective
inhibitors clearly prove the ‘‘high druggability’’ of the
MAGL protein (Bertrand et al., 2010), as originally predicted
only two years ago based on structural insights offered by
the MAGL crystal structure.
EXPERIMENTAL PROCEDURES
Materials
AM251 and CP55,940 were purchased from Tocris Cookson (Bristol, UK).
THL, BSA (fatty acid free), and reagents for functional autoradiography were
from Sigma (St. Louis, MO). KML29, MAFP, NAM, 2-AG, WWL70, and the
LC-MS/MS lipid standards were purchased from Cayman Chemicals (Ann
Arbor, MI). JZL184 was purchased from Cayman Chemicals or Sigma.
[35S]GTPgS (initial specific activity 1,250 Ci/mmol) was purchased from NEN
Life Science Products (Boston, MA). All other chemicals were of the finest
purity available. Detailed synthetic procedures are described in the Supple-
mental Experimental Procedures.
Endocannabinoid Hydrolase Assays
2-AG hydrolase assays based on fluorescent glycerol detection were con-
ducted in a 96-well format, as previously described (Navia-Paldanius et al.,
2012; Aaltonen et al., 2012). The amount of protein per well was 0.3 mg for
lysates of 2-AG hydrolase overexpressing HEK293 cells and 1 mg for brain
membranes and melanoma cell lysates. FAAH assays were conducted as
previously described (Saario et al., 2006) using rat forebrain membranes or
membranes prepared from COS-7 cells transiently overexpressing human
recombinant FAAH.
Functional Autoradiography of Endocannabinoid-Driven CB1R
Activity
Experiments were performed using 4-week-oldmaleWistar rats obtained from
the National Laboratory Animal Centre, University of Eastern Finland, Kuopio,
Finland. Approval for the harvesting of animal tissue was applied, registered,
and obtained from the local welfare officer of the University of Eastern Finland.
The experiments did not involve any in vivo treatment. The experiments were
performed using horizontal brain cryosections (thickness 20 mm), as previously
described (Paloma¨ki et al., 2007).Chemistry & Biology 20, 3LC-MS/MS Analysis of Tissue Endocannabinoid Levels
Triplicate slides, each with two horizontal brain sections, underwent the three-
step autoradiography mimicking protocol, as previously described (Paloma¨ki
et al., 2007). Sections were treated for 60 min and incubated thereafter for
90 min in assay buffer. Extraction of the endocannabinoids and the LC-
MS/MS instrumentation used in their analysis has been previously described
(Lehtonen et al., 2011).
ABPP of Serine Hydrolases
ABPP was conducted using the serine hydrolase-targeting FP probe TAMRA-
FP (ActivX Fluorophosphonate Probes, Thermo Fisher Scientific, Rockford, IL),
as previously described (Navia-Paldanius et al., 2012).
Supplemental Experimental Procedures
This section contains methods for assays of melanoma cell proliferation,
migration and invasion, molecular modeling, and mass spectrometric studies
of inhibitor-MAGL adducts.
Data Reproducibility and Statistical Analyses
All numerical data presented in figures and tables are mean ± SEM from at
least three independent experiments, with the exception of data in Figure 3,
where values are mean ± SD from a single experiment representing similar
data from two additional experiments. Inhibitor dose-response curves and
IC50 values derived thereof were calculated from nonlinear regressions using
GraphPad Prism 5.0 for Windows. Statistical comparisons were done using
one-way Anova, followed by Tukey’s nonparametric test. The significance is
denoted with asterixes (*, p < 0.05; **, p < 0.01; and ***, p < 0.001).
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, two tables, Supplemental
Results, Supplemental Discussion, and Supplemental Experimental Results
and can be found with this article online at http://dx.doi.org/10.1016/
j.chembiol.2013.01.012.
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